Searched for
CLINICAL ONCOLOGY
Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...- Can dogs smell cancer in humans? Bengaluru founders says with AI, dogs can detect seven cancer symptoms with 90% accuracyStartup Dognosis, based in Bengaluru, is creating an AI-driven, dog-assisted breath analysis to detect seven forms of cancer. Co-founded by...
- VIP culture in hospitals can compromise patient safety, equitable care: AIIMS doctorsAIIMS Delhi doctors discuss the ethical challenges posed by preferential treatment for VIP patients in healthcare. They emphasize that such...
- States urged to enforce ban on reuse of single-use medical devicesThe Directorate General of Health Services has issued a directive to prohibit the reuse of single-use medical devices. Violations by some p...
- 5 stocks with consistent score improvement and upside potential of up to 29% in 1 year, according to analystsDo not paint the whole market with one brush. Even in an extended fall like the current one, some parts of the economy still manage to hold...
- Paras Healthcare IPO Day 3: Check GMP, subscription status and key detailsParas Healthcare’s Rs 1,450 crore IPO enters its final bidding day with a muted response, while a grey market premium of around 2% signals ...
- Paras Healthcare IPO Day 2: GMP at 4%; check subscription status and key detailsParas Healthcare has launched its IPO, starting on October 21 and concluding on October 23. By October 22, participation had reached only 1...
- Paras Healthcare IPO opens for subscription: Check GMP, price band and key detailsParas Healthcare’s Rs 1,450 crore IPO opened for subscription on October 21 and closes on October 23, with a grey market premium (GMP) of a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up 32%, according to analystsHistory tells us that there is no way you can time the markets or predict its movement. But one thing can certainly be said: If the macro m...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
- Arizona University cancer researcher dies of the disease she fought to cure; her final wish was to raise $1.35 million for cancer researchDr. Rachna Shroff, a revered cancer researcher, sadly succumbed to terminal adenocarcinoma at the age of 47. Her condition emerged from a m...
- Pope Leo XIV, diagnosed with lung cancer, undergoes surgery. What is lung adenocarcinoma? 7 symptoms you should not ignoreAdenocarcinoma is a type of cancer that arises from glandular or secretory cells. Adenocarcinoma is the predominant variant of lung cancer....
- In a world no one forecast, own a business that outlives presidential social posts: 6 large-cap stocks with upside potential of up to 29%For quite some time now, it has become increasingly hard to make sense of what is happening in the world. The old understanding of what is ...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 20%In times like these, the market will have its green and red days. What matters, however, is not the colour of a single day, but the things ...
- British Indian pair, accused of cancer drug fraud, fight extradition to USA British Indian businessman and his ex-wife are fighting extradition to the US over allegations that they defrauded Medicare and other hea...
- When every number is a risk, the watchlist matters more than the buy list: 5 mid-cap stocks with upside potential of up to 26%There are times when the market forgives a weak quarter, and there are times when it does not. We are now in the second kind of market. The...
- Why is Summit Therapeutics share price up today by 22%?Summit Therapeutics share price is up today by 22% after biopharma firm announced AstraZeneca would invest $2 billion in it. British drugma...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25% according to analystsThe coming earnings season will reflect the impact of the bad monsoon, higher oil prices, and, in pockets, higher inflation. Given that, in...
- Govt, private hospitals likely to be graded on quality & safetyNiti Aayog is developing a national quality framework for public and private hospitals, aligned with international standards, to help patie...
- ET Startup Awards 2026: Theranautilus’ nanorobots will be ready for human trials by year-endTheranautilus won the Top Innovator category at The Economic Times Startup Awards 2026 for its unique nanorobot technology, which is built ...
Load More
